Table 2.

Comparison of maximum post-BD-FEV₁% between patients treated with and without daily oral GCs among the HSD3B1(1245) AA, AC, and CC genotypes^*

	SARP III			SARP I & II
HSD3B1(1245) Genotype	Not on GC	On GC	P value	Not on GC	On GC	P value†
AA
n	123	23		45	35
Pre-FEV1, % of predicted value	75.1 ± 18.3	54.3 ± 15.3	<0.001	63.4 ± 18.8	49.8 ± 17.1	0.001
Post-FEV1, % of predicted value	83.9 ± 18.8	64.2 ± 19.6	< 0.001	73.5 ± 15.9	63.7 ± 18.4	0.024
AC
n	107	24		49	30
Pre-FEV1, % of predicted value	75.6 ± 21.2	59.4 ± 19.8	0.001	66.9 ± 22.3	54.3 ± 18.3	0.008
Post-FEV1, % of predicted value	83.2 ± 20.5	67.7 ± 17.9	<0.001	77.2 ± 20.8	67.8 ± 20.3	0.07
CC
n	33	8		15	10
Pre-FEV1, % of predicted value	78.9 ± 16.3	73.4 ± 16.6	0.41	67.7 ± 22.5	66.7 ± 26.6	0.92
Post-FEV1, % of predicted value	89.2 ± 17.0	83.1 ± 14.4	0.32	78.2 ± 22.3	80.7 ± 16.2	0.76

^*Data are presented as mean ± SD for continuous variables and proportions or percentages for categorical variables.

^†P value comparing daily oral GC vs. no GC in each genotype group AA, AC, and CC.